Search details
1.
Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells.
Nat Immunol
; 17(12): 1467-1478, 2016 Dec.
Article
in English
| MEDLINE | ID: mdl-27776108
2.
Detection of dendritic cell subsets in the tumor microenvironment by multiplex immunohistochemistry.
Eur J Immunol
; 54(1): e2350616, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-37840200
3.
Proactive monitoring of drug-drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer.
Br J Cancer
; 2024 Jun 11.
Article
in English
| MEDLINE | ID: mdl-38862741
4.
Erratum: Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells.
Nat Immunol
; 18(2): 246, 2017 01 19.
Article
in English
| MEDLINE | ID: mdl-28102212
5.
Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis.
Int J Mol Sci
; 25(7)2024 Apr 03.
Article
in English
| MEDLINE | ID: mdl-38612799
6.
Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161.
Nat Immunol
; 12(11): 1055-62, 2011 Sep 11.
Article
in English
| MEDLINE | ID: mdl-21909091
7.
Pharmacokinetically-guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patients.
Br J Clin Pharmacol
; 88(4): 1930-1934, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34545619
8.
Hyperhydration with cisplatin does not influence pemetrexed exposure.
Br J Clin Pharmacol
; 88(2): 871-876, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34374116
9.
Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.
Oncologist
; 26(8): e1347-e1358, 2021 08.
Article
in English
| MEDLINE | ID: mdl-33111480
10.
Pharmacokinetically guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patients.
Br J Clin Pharmacol
; 88(8): 3920-3921, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35350084
11.
Inhibition of CSF-1R and IL-6R prevents conversion of cDC2s into immune incompetent tumor-induced DC3s boosting DC-driven therapy potential.
Cell Rep Med
; 5(2): 101386, 2024 Feb 20.
Article
in English
| MEDLINE | ID: mdl-38242119
12.
Analysis of stem-cell-like properties of human CD161++IL-18Rα+ memory CD8+ T cells.
Int Immunol
; 24(10): 625-36, 2012 Oct.
Article
in English
| MEDLINE | ID: mdl-22836020
13.
Integrating treatment cost reduction strategies and biomarker research to reduce costs and personalize expensive treatments: an example of a self-funding trial in non-small cell lung cancer.
Front Pharmacol
; 14: 1274532, 2023.
Article
in English
| MEDLINE | ID: mdl-38089058
14.
Prognostic Value of Nivolumab Clearance in Non-Small Cell Lung Cancer Patients for Survival Early in Treatment.
Clin Pharmacokinet
; 62(12): 1749-1754, 2023 12.
Article
in English
| MEDLINE | ID: mdl-37856040
15.
Evidence-based rationale for low dose nivolumab in critically ill patients with sepsis-induced immunosuppression.
Clin Transl Sci
; 16(6): 978-986, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37002646
16.
Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial.
Cancer Chemother Pharmacol
; 91(1): 33-42, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36413252
17.
A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer.
Target Oncol
; 18(3): 441-450, 2023 05.
Article
in English
| MEDLINE | ID: mdl-37081309
18.
Kidney Injury in Patients Treated with Immune Checkpoint Inhibitors Does Not Meet KDIGO-AKI Criteria.
Kidney360
; 3(3): 524-529, 2022 03 31.
Article
in English
| MEDLINE | ID: mdl-35582168
19.
Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer.
Eur Respir Rev
; 31(164)2022 Jun 30.
Article
in English
| MEDLINE | ID: mdl-35705208
20.
Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination.
J Immunother Cancer
; 10(10)2022 Oct.
Article
in English
| MEDLINE | ID: mdl-36252995